ASTS
AST SpaceMobile, Inc.
ASTS has the edge over DOCN overall, supported by stronger modeled upside and stronger valuation.
DOCN
DigitalOcean Holdings, Inc.
DOCN trails on the overall score without a compensating advantage in the available component scores.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
DOCN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Strong | |
| Strong |
DOCN's revenue, cash flow and balance sheet are currently strong, and its profitability is stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
DOCN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 25x | $7.61 | -92% |
| Fair | 46x | $13.68 | -85% |
| Forward | 55x | $90.07 | — |
| Expensive | 68x | $20.36 | -77% |
| Current | 300x | $90.07 | — |
Historical ranges are pointers, not guarantees.
DOCN's PE is in its expensive range at 300x. If earnings grow as analysts expect, today's price would be 55x next year's earnings, in its fair range.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
DOCN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for DOCN, but weaker profitability. However, they disagree widely on these estimates.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
DOCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.64 | +448% |
| Q3 2026 | $0.30 | -88% |
| Q2 2026 | $2.18 | +68% |
| Q1 2026 | $2.28 | +105% |
| Q4 2025 | $2.52 | +190% |
| Q3 2025 | $2.48 | +195% |
| Q2 2025 | $1.30 | +83% |
| Q1 2025 | $1.11 | +113% |
| Q4 2024 | $0.87 | +335% |
DOCN has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS's revenue has grown year over year for 11 quarters in a row: $42M last quarter, up 187% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
DOCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $321.2M | +40% |
| Q2 2026 | $281.2M | +29% |
| Q1 2026 | $257.9M | +22% |
| Q4 2025 | $242.4M | +18% |
| Q3 2025 | $229.6M | +16% |
| Q2 2025 | $218.7M | +14% |
| Q1 2025 | $210.7M | +14% |
| Q4 2024 | $204.9M | +13% |
DOCN's revenue has grown year over year every quarter since early 2021: $321M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -9.3 points |
| Q2 2026 | 10% | -5.8 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 16% | +0.1 points |
| Q3 2025 | 20% | +7.2 points |
| Q2 2025 | 16% | +4.7 points |
| Q1 2025 | 18% | +12 points |
| Q4 2024 | 16% | +9.8 points |
DOCN has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
DOCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $137.7M | +56% |
| Q2 2026 | $68.4M | +15% |
| Q1 2026 | $6.9M | +226% |
| Q4 2025 | $31.1M | +19% |
| Q3 2025 | $88M | +450% |
| Q2 2025 | $59.3M | +50% |
| Q1 2025 | $2.1M | -91% |
| Q4 2024 | $26.1M | -7.9% |
DOCN has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
DOCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.4% | -11.9M shares |
| 1 year | +8.7% | +9.2M shares |
| 3 years | +12% | +12M shares |
| 5 years | +6.2% | +6.7M shares |
| Available history | +32% | +27.6M shares |
DOCN has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $2.9M |
| Q2 2025 | $20.1M |
| Q1 2025 | $59.1M |
| Q4 2024 | $29.9M |
DOCN hasn't bought back shares in the past year.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
DOCN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 3.5x | Elevated |
| Q3 2025 | 3.8x | Elevated |
| Q2 2025 | 4.3x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.8x | High |
DOCN has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
DOCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 11.0 | Oversold |
DOCN's weekly RSI is 42 (neutral) and its Stochastic is 11 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
DOCN PE vs Technology Sector
| Metric | DOCN | Sector median | Relative |
|---|---|---|---|
| PE | 300x | 28x | 978% above |
| PE % | 100 | 41 | 59 pts above |
DOCN is trading at 300x earnings, a 978% premium to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
DOCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $107.3 | 16% below |
| 20 week MA | $116.3 | 23% below |
| 50 week MA | $101.1 | 11% below |
| 100 week MA | $68.0 | 33% above |
| 200 week MA | $51.5 | 75% above |
DOCN has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
DOCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $41.6 | $81.3 | +95% |
| 2022 | $81.3 | $24.8 | -70% |
| 2023 | $24.8 | $36.7 | +48% |
| 2024 | $36.7 | $34.9 | -4.8% |
| 2025 | $34.9 | $49.5 | +42% |
| 2026 YTD | $49.5 | $90.1 | +82% |
DOCN has the edge over ASTS on returns for 2026, with the stronger performance.